Dr. Kwon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 Cardinal Way
2nd Floor
Redwood City, CA 94063- Is this information wrong?
Education & Training
- University of California (San Francisco)Residency, Dermatology, 1997 - 2000
- Kaiser Permanente Northern California (Oakland)Internship, Internal Medicine, 1996 - 1997
- University of California San Francisco School of MedicineClass of 1996
Certifications & Licensure
- CA State Medical License 1998 - 2024
- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FAAD) American Academy of Dermatology
Publications & Presentations
PubMed
- 15 citationsValidation of psychometric properties of the itch numeric rating scale for pruritus associated with prurigo nodularis: a secondary analysis of a randomized clinical trialMiriam Kimel, Claudia Zeidler, Paul Kwon, Dennis A. Revicki, Sonja Ständer> ;JAMA Dermatology. 2020 Dec 1
- 23 citationsPhase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trialAlbert S. Chiou, Sara Choi, M. Barriga, Yana Dutt-Singkh, Daniel Solis, J. Nazaroff, I. Bailey-Healy, Shufeng Li, Kim Shu, Mark Joing, Paul Kwon, Jean Y. Tang> ;Journal of the American Academy of Dermatology. 2020 Jun 1
- 73 citationsSerlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.Sonja Ständer, Paul Kwon, Joe Hirman, Andrew J. Perlman, Elke Weisshaar, Martin Metz, Thomas A. Luger> ;Journal of the American Academy of Dermatology. 2019 May 1
Press Mentions
- Serlopitant’s Potential to Manage Itch in EB Patients Shown in Exploratory TrialJune 6th, 2018
- Stanford Researchers Presented Results from an Exploratory Study of Serlopitant for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients Indicating Reduction in Itch with Serlopitant TreatmentMay 21st, 2018
- Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of DermatologyFebruary 20th, 2018
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: